Once-Weekly Semaglutide Versus Sodium-Glucose Co-transporter 2 Inhibitors: Real-World Impact on Weight, HbA1c, and Healthcare Resource Utilization in Type 2 Diabetes (PAUSE)

被引：0
|
作者：
James Amamoo [1 ]
Riddhi Doshi [2 ]
Joshua Noone [1 ]
Lin Xie [1 ]
Cory Gamble [1 ]
Mico Guevarra [1 ]
Victoria Divino [2 ]
Justin Chen [2 ]
Aaron King [3 ]
机构：
[1] Novo Nordisk Inc.,
[2] IQVIA,undefined
[3] MedFirst Primary Care – Quarry,undefined
来源：
Diabetes Therapy | 2025年 / 16卷 / 5期
关键词：
BMI; GLP-1 receptor agonist; HbA1c; Healthcare resource utilization; Real-world evidence; Semaglutide; SGLT2i; Type 2 diabetes; Weight;
D O I：
10.1007/s13300-025-01721-y
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1033 / 1048
页数：15
相关论文
共 50 条
  • [31] Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting
    Uzoigwe, Chioma
    Liang, Yuanjie
    Whitmire, Sarah
    Paprocki, Yurek
    DIABETES THERAPY, 2021, 12 (05) : 1475 - 1489
  • [32] Real-World Use of Once-Weekly Semaglutide in Thai Patients With Type 2 Diabetes Mellitus in a Private Hospital Setting
    Thewjitcharoen, Yotsapon
    Yenseung, Nalin
    Butadej, Siriwan
    Nakasatien, Soontaree
    Chotwanvirat, Phawinpon
    Chatchomchuan, Waralee
    Wanothayaroj, Ekgaluck
    Krittiyawong, Sirinate
    Himathongkam, Thep
    JOURNAL OF THE ASEAN FEDERATION OF ENDOCRINE SOCIETIES, 2023, 38 (01): : 21 - 28
  • [33] Sodium-Glucose Co-Transporter 2 Inhibitors and the Risk of Genitourinary Infections at HbA1c ≥10%: A Population Health-Based Retrospective Review
    Ashby, Bryce
    Kawaguchi-Suzuki, Marina
    Holman, Yvette Grando
    Harris, Jackie
    Chlasta, Rachel
    Wargo, Ryan
    ANNALS OF PHARMACOTHERAPY, 2025, 59 (03) : 238 - 243
  • [34] Real-world safety profile of once-weekly semaglutide in people with type 2 diabetes: Analysis of pooled data from the SemaglUtide Real-world Evidence (SURE) programme
    Yale, Jean-Francois
    Major-Pedersen, Atheline
    Catarig, Andrei-Mircea
    Jain, Rashmi
    Menzen, Markus
    Holmes, Patrick
    DIABETES OBESITY & METABOLISM, 2024, 26 (10): : 4429 - 4440
  • [35] Effect of sodium-glucose co-transporter inhibitors on arterial stiffness in patients with type 2 diabetes mellitus
    Szigeti, J.
    Bukva, M.
    Gaszner, B.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [36] Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors in Thai adults with type 2 diabetes mellitus: a real-world study
    Sriphrapradang, Chutintorn
    Thewjitcharoen, Yotsapon
    Buranapin, Supawan
    Sawanyawisuth, Kittisak
    Yenseung, Nalin
    Ubonchareon, Wisawa
    Limpijankit, Laddawan
    Himathongkam, Thep
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (10) : 1601 - 1610
  • [37] Sodium-Glucose Co-transporter 2 Inhibitors Versus Metformin as the First-Line Treatment for Type 2 Diabetes: Is It Time for a Revolution?
    Koufakis, Theocharis
    Papazafiropoulou, Athanasia
    Makrilakis, Konstantinos
    Kotsa, Kalliopi
    CARDIOVASCULAR DRUGS AND THERAPY, 2023, 37 (02) : 315 - 321
  • [38] Change in HbA1c Across the Baseline HbA1c Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents
    Raffaella Gentilella
    Irene Romera
    Claudia Nicolay
    Raffaella Buzzetti
    Luis Alberto Vázquez
    Giorgio Sesti
    Diabetes Therapy, 2019, 10 : 1113 - 1125
  • [39] Sodium-Glucose Co-transporter 2 Inhibitors Versus Metformin as the First-Line Treatment for Type 2 Diabetes: Is It Time for a Revolution?
    Theocharis Koufakis
    Athanasia Papazafiropoulou
    Konstantinos Makrilakis
    Kalliopi Kotsa
    Cardiovascular Drugs and Therapy, 2023, 37 : 315 - 321
  • [40] Change in HbA1c Across the Baseline HbA1c Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents
    Gentilella, Raffaella
    Romera, Irene
    Nicolay, Claudia
    Buzzetti, Raffaella
    Alberto Vazquez, Luis
    Sesti, Giorgio
    DIABETES THERAPY, 2019, 10 (03) : 1113 - 1125
12345